Velano Vascular is on a mission to bring compassion to healthcare and make painful blood draws more pleasant for patients. So far, they’re succeeding. They’ve received their 3rd FDA-clearance to help children and adults who cringe at the sight of needles.
Needlephobia affects 24% of adults and 63% of children.
The Boy Who Cried Wolf may come to mind when we talk about no more needles for blood draws because of ill-fated Theranos. They’re the overly-hyped biotech start-up currently under federal investigation by the S.E.C. and U.S. Attorney’s office. Patients initially thrilled about no more needles got hoodwinked by fake news.
Meet the Real Deal.
Velano Vascular creates a single-use, disposable device called PIVO.
It attaches to a peripheral IV line, in hospital inpatients, allowing for lab quality blood samples to be drawn back through the IV –without requiring venipuncture (needle sticks or drawing blood from central lines) .
Many of the questions Therano’s CEO never answered, avoided or even got asked by reporters is welcomed by Velano Vascular’s CEO, Eric Stone, who I interviewed.
WHAT IS PIVO AN ACRONYM FOR?
ERIC STONE, CEO, VELANO VASCULAR: PIVO derives from “peripheral intravenous catheter,” or PIV, which is a medical term for the standard IV most hospital patients are hooked up to in order to receive intravenous fluids..
WHAT IS PIVO?
STONE: PIVO is a single-use, disposable device that attaches temporarily to an IV line, allowing for needle-free blood draws from this existing line.
HOW DOES IT WORK?
STONE: It enables blood draws to be taken by clinicians from the same intravenous (IV) catheter most hospital patients already have inserted in their arms, instead of poking them again each time they need their blood drawn and instead of accessing larger catheters (Central Venous Catheters) which raise different challenges associated with each time they are accessed.
WHO DOES THIS DEVICE HELP PEOPLE?
STONE: The device works for any patient with an IV catheter. Of course, children tend to more commonly have an acute fear of needles, so it can make pediatric care less invasive and painful.
There are also an estimated 30% of our hospital inpatients that are classified as DVA (Difficult Venous Access) because of aging, obesity, disease and more.
PIVO helps practitioners capture critical labs from these growing populations of patients who otherwise may take significant time and expense.
STONE: Also, those in hospitals or other inpatient settings, where the average length of stay is almost 5 days in the U.S. require daily or more frequent blood draws. Many of these patients have problematic veins or skin, which requires a lot of poking and prodding to draw blood. PIVO tackles these issues head on.
According to the CDC, an estimated 35M inpatient stays occur in the U.S. alone each year. So, PIVO is set to help many millions of Americans, not to mention those inpatients around the world.
HOW IS PIVO MORE COMFORTABLE & LESS DANGEROUS FOR PATIENT?
STONE: For patients who have their blood drawn for a check-up once a year in an outpatient setting, blood draws are not that disruptive. For a “frequent flyer” in the hospital, or a DVA (difficult venous access) patient –noted as such upon admission or who has become DVA after 10 or 20 days in the hospital feeling like a pin cushion –removing the needle from the procedure can have a lifelong impact.
Enabling practitioners to avoid accessing central lines (large, surgically-placed catheters) for blood draws aims to reduce the risks of Central Line Associated Blood Stream Infection.
Further, removing the needle from blood draws helps avoid risk of injury and infection for our phlebotomists, nurses and physicians. Hospital leadership is recognizing that an important alternative to a prevalent practice is now available.
IF I GET BLOOD WORK FROM AN ANNUAL PHYSICAL WILL THEY USE PIVO?
STONE: PIVO requires a Peripheral IV catheter in order to access the vein. The IV line serves as a temporary conduit to the vein, so without the IV line PIVO cannot access the vein.
The IV line serves as a temporary conduit to the vein, so without the IV line, PIVO cannot access a patient’s blood. As such, this procedure is most appropriate for the hospital inpatient setting.
I do envision PIVO will adopted in other care settings, where patients possess an IV line and require frequent blood draws, but the annual physical unfortunately is not one of these.
WHY AREN’T IV’S GOOD FOR DRAWING BLOOD WITHOUT PIVO?
STONE: IV’s are essentially plastic tubes which overtime become soft, like a noodle. While a noodle is fine for injecting fluids and medications into a patient, its soft walls collapse under the negative pressure of suction when you try to take fluids out.
There are other reasons why IV’s are less-than-optimal for drawing blood back, but these are quite complex in nature and we’re only just now uncovering some of the novel reasons through our research with leading clinical collaborators.
PIVO simply inserts a small, stiffer tube inside the existing IV tube for the purpose of drawing blood.
It works by propping open and unkinking the IV tube temporarily while enabling lab quality blood be collected.
HOW WAS THE IDEA FOR PIVO ORIGINALLY DEVELOPED?
STONE: Velano’s co-founder and physician, Pitamber Devgon had an elderly patient with bruises up and down her arms from repeated needle sticks. That patient asked him why he was continually sticking her with needles when she already had an IV catheter in her vein. He didn’t know, but began exploring if it was possible to draw lab quality samples out of the IV line using a separate device.
Stone, a Wharton MBA shares, “Most of my career has been in healthcare, plus I am a needle phobic following my childhood diagnosis with Crohn’s disease as a teenager. So, when I was looking for a company start and a product to bring to market and my former graduate school classmates introduced us, I was instantly engaged following years as a serial healthcare entrepreneur and patient advocate. From that connection, Velano was born. “
Velano first won FDA approval for PIVO in 2015, and has also obtained multiple U.S. and international patents for it, with additional applications outstanding in the U.S. & abroad.
STONE: “Five years from now,” asserts Stone, “I believe, without a doubt that PIVO will be the standard of care for inpatient blood draws and vascular access.”
Thanks for a great interview and innovation for healthcare consumers! -Maria Dorfner
http://velanovascular.com
MEDIA: Contact: Michael Azzano at 415-596-1978 to set up telephone or on-camera interviews with patients or Eric Stone, CEO, Velano Vascular.
____________________________________________________
RELATED NEWS:
A year ago, Forbes contributor Robert Reiss called Eric Stone “The Steve Jobs of Drawing Blood” and tested PIVO himself. Reprint of article below courtesy of Reiss.
The Steve Jobs Of Drawing Blood
by Robert Reiss , FORBES CONTRIBUTOR (specializing in writing about CEOs)
Opinions expressed by Forbes Contributors are their own.
I was recently at a board meeting at Griffin Hospital and our CEO was telling us about a new product that could transform perhaps the most ubiquitous healthcare practice – drawing blood.
The concept from a company called Velano Vascular repurposes the IV most hospital patients already have in their arms so blood can be drawn without having their veins repeatedly stuck by needles.
It aims to eliminate the associated negatives of traditional blood drawing: the pain and anxiety, injuries, excessive time and cost.
It seemed like such a revolutionary solution to a broad issue – sort of like in 1892 when Keds invented sneakers – and I was curious to understand if this was truly an historic moment where the age old process of drawing blood could once and for all be revolutionized.
It reminded me of one of my first CEO interviews back in 2007 with Jay Walker, the founder of Priceline when he described the driving force behind one of his over 700 patents, “The key to successful innovation is having a better solution for something that’s used everywhere and every day.”
So I decided to experience this innovation firsthand and a few weeks later I intentionally became a patient and experienced this new needleless way to draw numerous samples of blood.
I was amazed, the nurses were able to draw blood easily, and to do so as many times as they wanted without ever having to stick a needle in me again.
I was next introduced to the founder of Velano Vascular, Eric Stone, who I now admiringly call the Steve Jobs of drawing blood, and below are a few insights from our conversation:
Robert Reiss: How much blood is currently being drawn and what are the problems with the current system?
Eric Stone: Blood draws are not fun – and they are overlooked and underappreciated…except by patients. They are likely the most common invasive medical procedure, with an estimated half a billion in U.S. hospitals alone conducted every year, and two to three times this number across all hospitals worldwide annually.
Recognizing that the U.S. represents nearly 40 million inpatient admissions annually, with an average length of stay of five days, and a conservative estimate of two blood draws per patient per day, we are easily conducting hundreds of millions of inpatient draws each year quite readily.
This does not even take into account other non-hospital settings where patients require regular blood draws, such as long-term care facilities, skilled nursing homes and more – all locations where patients may have a peripheral IV (PIV) catheter indwelling (a requirement for our innovation to be relevant).
For a procedure that informs nearly 70% of all clinical decisions, it is remarkable that the last major innovation was the abandonment of bloodletting centuries ago.
Whether you’re the parent of a sick child or the son or daughter of an elderly parent, repeat hospitalizations and frequent blood draws hit home for just about everyone. It’s scary, it hurts, and it’s critical that we begin to pay attention and stop taking the steely reserve of our patients for granted.
Herein lies the rub. People scared of needles (trypanophobia) avoid necessary tests and treatment, needles injure healthcare workers more than 2 million times a year in accidents that can lead to serious infection, and the list of dysfunction goes on.
The way we draw blood today has real emotional, clinical and financial consequences. We can, and we must, do better. We can start by paying attention.
Reiss: What specifically is different about the Velano Vascular product?
Stone: Velano’s FDA-approved PIVO™ is a disposable, needle free device that connects to a patient’s existing IV catheter, enabling blood draws during their entire hospital stay without requiring subsequent needle sticks.
It turns out that IVs are great at putting fluids into the body but unreliable at pulling them out – that’s why patients receive so many needle sticks while in the hospital.
PIVO turns the routine IV into a reliable conduit for drawing high quality blood samples. This is an elegant solution to a centuries-old problem.
Now, patients no longer need to feel like a “pin cushions” or experience abrupt awakenings between 2:00 am and 6:00 am for the nighttime needle stick – when 40% of blood draws occur.
The company was founded based on a simple idea back in 2012, and subsequently PIVO has been used in clinical pilots and trials at a number of leading U.S. hospitals since receiving regulatory clearance in early 2015.
It has won a number of awards, including the Frost & Sullivan New Product Innovation Award for Vascular Access in 2016 and the Sheikh Zayed Institute for Pediatric Surgical Innovation competition at Children’s National Health in Washington, DC.
Reiss: What are the strengths and weaknesses of your methodology on quality outcomes?
Stone: Velano is most often measured by the clinical quality of blood samples drawn and its impact on both practitioner and patient experience.
In thousands of patients, the quality of our blood samples has been definitive and easy to measure, both through clinical studies and “real world,” commercial use.
Blood drawn from PIVO has similarly low hemolysis rates (blood cell shearing or tearing that can relegate a patient to a re-draw and delays in essential care) to needle draws.
Clinical study efforts and pilots with some of the country’s leading healthcare institutions such as University Hospitals Cleveland, Intermountain Healthcare, The University of Pennsylvania Hospital and Harvard’s Brigham and Women’s Hospital reflect clinically appropriate laboratory results – confirming that blood drawn with our compassionate technology can become a standard of care for clinical decision-making.
Practitioner and patient experience is harder to quantify, but our surveys and testimonials to-date are resoundingly positive. In fact, patients who receive PIVO draws are requesting PIVO when transferred to floors in the hospital that are not participating in our pilots or upon readmission to the hospital. They are actually asking for the product – it is remarkable.
The onus is on Velano to continue improving our quality measurements to undeniably prove this innovation is truly a win-win-win, as we seek to elevate the quality of care and outcomes for patients, practitioners and hospitals alike.
Reiss: What is the financial model for a user and what is the economic impact nationally?
Stone: The cost of a blood draw is not just the $1 or less spent for a needle. Instead, it is the many billions of dollars a year spent on wasted materials, rejected blood samples, patient and practitioner risks, delayed results, labor costs, central line escalations, and more resulting from this less-than-desirable and madly inefficient procedure.
Some of the financial downsides of traditional blood draw standards are somewhat obscure, however we’ve helped our hospital partners understand the current impact by simply asking sincere questions, seeking to learn, and paying a modicum of attention to the topic.
Think about the blood draw on an elderly or obese or diabetic patient that can take as long as an hour of a nurse’s time and 2-3 needles to find a vein and collect an adequate sample.
Consider that even one single case of an employee blood borne pathogen transmission from a needle stick can cost millions of dollars in exposure for a hospital.
For PIVO, we understand that in an environment of increasing health industry price transparency and pressures, when our entire healthcare system is experiencing economic upheaval, and cost neutrality is required for rolling out true innovation in hospitals.
Reiss: Why did you start Velano Vascular and what’s your vision?
Stone: The reason why is very simple – because I am first and foremost a patient, and I am a parent. 25 years ago I was diagnosed with Crohn’s disease, launching me on a lifelong journey as a healthcare entrepreneur, patient advocate, and National Trustee of the Crohn’s and Colitis Foundation of America. Since a young age, I’ve been motivated by IMPACT.
I started Velano in partnership with an intellectually curious physician inventor intrigued by a seemingly simple question posed by his patient – “why are you repeatedly sticking me with needles [when I already have an IV line in my arm]?”
This simple, yet elegant idea resonated strongly with me, for I am needle-phobic myself, and I have been that “tough stick” patient during my hospital stays. Today, this brilliant idea has become reality.
My vision for Velano is to touch every human being on the planet; for we will all spend time in a hospital at some point in life, and we will certainly need our blood drawn when we do.
http://velanovascular.com
MEDIA: Contact: Michael Azzano at 415-596-1978 to set up telephone or on-camera interviews with patients or Eric Stone, CEO of Velano Vascular
Maria Dorfner founder of NewsMD: What’s Hot in Health
NewsMD Communications was founded in 1998 to educate healthcare consumers by connecting medical + media to inspire and empower millions to want to live healthy.
In 1993, Maria created Healthcare Consumers, Healthy Living, Lifestyles & Longevity and Healthcare Practitioners. The shows aired on CNBC, which she helped launch in 1989. She is the founder of Cleveland Clinic News Service, helped launch MedPage Today (sold to CNN) and wrote & produced 21st Century Medicine for Discovery Health. Her awards include Freddie for Excellence in Medical Reporting, Outstanding Leadership Abilities, Media Recognition, Who’s Who, Medical Reporting Scholarship. She produced for Journal of the American Medical Association (JAMA) Report, talk shows & reality programming.
She began as an intern at NBC 
SHOW in NYC in 1983.
This is her blog.
Have an innovative solution healthcare consumers|media should know about?
Contact: maria.dorfner@yahoo.com
Response only if it’s a story of interest. Thank you.
Like this:
Like Loading...
Foll
Sathya Elumalai, MS, MBA, Founder and CEO of Adair Health, is a medical device executive with over 15 years of experience working with payers, providers, pharmaceutical companies, and patients. At Multisensor Diagnostics (MDx), Elumalai has developed a revolutionary tricorder-style rapid medical assessment device and artificial intelligence-enabled triaging system for efficient home management of chronic disease.
Creator: Ami Shah
NewsMD: What's Hot in Health 